Medicago Announces Positive Phase 1 Results for Its COVID-19 Vaccine Candidate
Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to report interim results of the Phase 1 clinical trial of its plant-derived vaccine for COVID-19. The results of the trial demonstrated that 100 per cent of subjects developed a promising antibody response after two doses of Medicago’s COVID-19 adjuvanted vaccine candidate.
“These are very promising results. After two doses, the adjuvanted vaccine candidate induced robust neutralizing antibody and cellular immune responses which is encouraging and support further clinical evaluation,” said Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago. “We also observed that the antibody levels were higher after vaccination than those observed in convalescent sera from people who recovered from the disease.”
There were no severe adverse events reported and reactogenicity events were generally mild to moderate and short in duration.
The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy subjects, male and female aged 18-55, and evaluated dosages of 3.75, 7.5 or 15 micrograms of the recombinant Coronavirus Virus-Like Particle (CoVLP) vaccine candidate alone or with an adjuvant in a prime-boost regimen. Medicago tested its vaccine candidate with each of the two adjuvants – GSK’s proprietary pandemic adjuvant technology and Dynavax’s CpG 1018™. An adjuvant can be of particular importance in a pandemic situation as it may boost the immune response and reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and therefore allowing immunization of the greatest number of people. Significant humoral and cell-mediated immune responses have been observed with both adjuvants. Based on the Phase 1 data, Medicago plans to proceed with the Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.
“The positive results of our Phase 1 clinical trial are a step forward in the fight against the COVID-19 pandemic and we are confidently moving forward to our Phase 2/3 trial. We’re pleased that Medicago’s innovative manufacturing technology is helping to diversify the classes of COVID-19 vaccines candidates in development. In addition to supplying up to 76 million doses to the Government of Canada, we are ready to participate globally in the fight against COVID-19,” said Dr. Bruce D. Clark, President and CEO of Medicago. “We would like to express our gratitude to the clinical trial participants who have generously dedicated their time to support the advancement of Medicago’s COVID-19 vaccine candidate. We also would like to extend our thanks to our partners GSK and Dynavax, as well as the clinical investigators.”
The data from the interim analysis have been published on an online preprint server at medRxiv.org.
About Phase 1 results summary
- Side effects were mainly mild to moderate and of short duration with no serious adverse events. Safety follow-up continues.
- Phase 1 immunogenicity results demonstrate that adjuvants have the potential to improve humoral and cellular immune responses compared to the non-adjuvanted formulations.
- All subjects in the group with GSK’s pandemic adjuvant developed anti-spike IgG antibodies after a single dose of vaccine – either 3.75, 7.5 and 15 µg.
- 100 per cent of participants who received an adjuvanted formulation developed neutralizing antibody responses after Dose 2 for all dose groups.
- Anti-spike IgG and viral neutralization responses compared favorably to responses from COVID-19 positive patients outside of the study.
- GSK’s pandemic adjuvant was dose-sparing, with the lower 3.75 µg dose of CoVLP performing comparably with the 7.5 or the 15 µg doses.
- Cellular Th1 immune responses of participants who received 3.75 or 7.5 µg doses were significantly higher in the adjuvanted formulations
- CoVLP finished product is a liquid formulation that can be stored at 2°C to 8°C, easing cold chain management with existing vaccine infrastructure.
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Local Loyal, Spice Seeking, Mindful Mixologists - These Are the Spirits Consumers of 2022, According to the Annual Bacardi Cocktail Trends Report6.12.2021 15:00:00 EET | Press release
Bacardi Limited, the world's largest privately-held spirits company, releases its third annual Bacardi Cocktail Trends Report , looking ahead at the key trends impacting the business of cocktails in 2022. The report is created in collaboration with The Future Laboratory (TFL) and draws from Bacardi-led and external research to unveil the undercurrents transforming everything from drinks desired, flavor expectations, and imbibing occasions through to ethical action and ways of creating cocktails. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211206005158/en/ The third annual Bacardi Cocktail Trends Report spotlights the macro-trends defining how, what, where, and why consumers are sipping spirits in 2022. (Graphic: Business Wire) “As 2022 brings new perspective, people are coming together with a strong desire to ‘Make Moments Matter’. At Bacardi, we are driven by this purpose – with a family of premium spirit brands that are
Galderma Announces New Data Demonstrating the Positive Anti-inflammatory Effect and Mode of Action of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis6.12.2021 12:00:00 EET | Press release
Galderma today announced that the Journal of Allergy and Clinical Immunology has published gene expression data that demonstrate the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis (PN), confirming the potential of nemolizumab as a major player in the treatment of PN, effectively reducing both pruritus and severity of skin lesions in PN patients. “Transcriptome data is an important step in validating the therapeutic effect of nemolizumab through a deeper understanding of the mode of action at a cellular level. With these data, we are advancing dermatology and contributing to improving our understanding of PN. These data emphasize that nemolizumab may have a key role to play for patients with moderate to severe PN. This will be confirmed by our ongoing nemolizumab Phase 3 studies in PN.” Dr. Baldo Scassellati Sforzolini Global Head of R&D, GALDERMA PN is a rare, potentially debilitating, chronic skin condition wit
iProov and Eurostar Launch Trial to Provide Contactless Travel at London St Pancras International6.12.2021 10:00:00 EET | Press release
iProov, the world leader in biometric face authentication technology, and Eurostar, the high-speed passenger rail service linking the UK with mainland Europe, have announced that their trial of a contactless fast-track service, SmartCheck, is now live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211205005029/en/ iProov and Eurostar announce contactless travel trial is live at London St Pancras International (Photo: Business Wire) SmartCheck enables passengers to complete secure ticket verification and UK exit check on their mobile devices prior to travel. As part of the trial, Business Premier and Carte Blanche ticket holders will be able to scan their identity documentation using their iPhones before arriving at the station, completing a brief biometric face scan to verify that they are the genuine holder of the identity document. The biometric face verification, which uses iProov’s Genuine Presence Assurance technology,
2021 World Conference on Science Literacy in Focus: Science Literacy for a Green Future6.12.2021 06:53:00 EET | Press release
On November 30, the 2021 World Conference on Science Literacy (WCSL) kick started in Beijing. With the theme of “Science Literacy for a Green Future”, the conference invited esteemed decision-makers, top scientists, renowned scholars, as well as leaders and representatives from key scientific and technological organizations (such as the United Nations Educational, Scientific and Cultural Organization, International Science Council, World Federation of Engineering Organizations, and The World Academy of Sciences for the advancement of science in developing countries). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211205005040/en/ Improving public science literacy and promoting low-carbon green transformation are among the topics they discussed. Together, the attendees shared their ideas, results, and experience of using science for green development, as well as contributing to an effective communication and partnership mecha
Alibaba Group Announces CFO Succession6.12.2021 03:22:00 EET | Press release
Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988, “Alibaba” or “Alibaba Group”) today announced that Toby Xu, Deputy Chief Financial Officer, will succeed Maggie Wu as the Company’s Chief Financial Officer, effective April 1, 2022. Maggie will continue as a partner in the Alibaba Partnership and serve as an executive director on the Alibaba board. “Maggie has made exceptional contributions that are instrumental to Alibaba’s achievements to date. Since joining Alibaba almost fifteen years ago, Maggie has helped lead three successful company public listings as CFO: Alibaba.com on the Hong Kong Stock Exchange in 2007, and Alibaba Group Holding on the New York Stock Exchange in 2014 and on the Hong Kong Stock Exchange in 2019. She has built and nurtured a finance team with professional capabilities and accomplishments second to none, and has served as our bedrock in pursuing Alibaba’s strategies and business development. Maggie is forever calm and unflappable, regardless of ups and
NextSense Emerges to Unlock Brain Health with Key Partners UCB, Heraeus, UC San Diego, and Emory University3.12.2021 18:00:00 EET | Press release
NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time. NextSense unlocks brain health with real world data insights and practical, scientific wisdom for daily living. Traditional brain health monitoring technology like EEG machines and polysomnograms are too bulky for home use, requiring patients to stay overnight at hospitals or sleep study clinics for observation. The high cost of care and lack of comfort of these devices makes long-term and continuous monitoring nearly impossible. Not only are these data based on a single timeframe, they observe what is anything but an ordinary night’s sleep. And for anyone living with epilepsy, the unpredictability of seizures makes direct observation and high-quality data-gathering exceedingly rar
Healthcare+ Expo Taiwan to Build an Ecosystem of Digital Transformation in Healthcare3.12.2021 17:15:00 EET | Press release
One of the largest trade fairs in the APAC region- the Healthcare+ Expo Taiwan- takes place on 2 to 5 December in Taipei. The Expo displays Taiwan’s strength in AI, Cloud-based Applications, Flat Panels, IoT and Technologies that make up Metaverse, reflecting the trend on digital transformation in healthcare driven by the global pandemic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211203005002/en/ Expand Businesses into growing markets in the APAC region, with Healthcare+ B2B. Join medical institutes and companies in the fields of pharmaceuticals, biotechnology, health/ information technology, electronics and manufacturing to promote products, build partnerships and seize supply-demand opportunities. (Graphic: Business Wire) The Expo has an all-star lineup of corporates, including Acer, Asus, AUO, Delta Electronics, Innolux, Quanta and Wistron, demonstrate their technologies and solutions tailored to digital transformati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom